Raymond A. Huml, MS, DVM, RAC is Vice President of Strategic Drug Development and Head of Global Biosimilars Strategic Planning for IQVIA’s Biosimilars Center of Excellence. Dr. Huml has almost 30 years of experience in the clinical and biopharmaceutical industries.
Dr. Huml previously held the position of Head of Global Due Diligence for Quintiles Corporate Development and identified risks associated with Quintiles global, product-based investments, which resulted in over $2.9b in capital committed to partnerships of all sizes.
Previously, Dr. Huml worked in the Center for Integrated Drug Development (now Strategic Advisory Services), Biostatistics, Medical Writing, and Regulatory Affairs Departments in Quintiles (legacy) Clinical Development Services group.
Dr. Huml has authored or co-authored over 70 articles, 11 book chapters and three books on topics such as due diligence, competitive intelligence, biosimilars and muscular dystrophy. In 2010, he published the first individually authored book for RAPS titled, “Introduction to the Due Diligence Process.” In 2015, Dr. Huml edited and wrote or co-wrote eight chapters for the Springer book titled, “Muscular Dystrophy: A Concise Guide”, which covers all types of MD.
In 2003, he was awarded North Carolina Veterinary Medical Association's Young Veterinarian of the Year Award. In 2004, he was awarded Regulatory Affairs Professional’s Society (RAPS) New Professional Award. He has also received numerous Quintiles awards including the Distinguished Performance Award, Clinical Development Services President's Award and the Chairman's Award.
Dr. Huml is a Returned Peace Corps Volunteer having served in Ghana, West Africa and currently sits on North Carolina State University’s Board of Visitors. He holds an MS in Biology from East Stroudsburg University and his DVM from North Carolina State University’s College of Veterinary Medicine and has earned the RAC (US) Certification.
Monday, September 23
10:30 AM – 12:00 PM